Latest Breaking News On - Aurka pathway - Page 1 : comparemela.com

Alisertib as monotherapy and in combination with fulvestrant stands at the forefront of the clinical investigation of selective AURKA pathway inhibition in patients with endocrine-resistant advanced breast cancer, according to Tufia C. Haddad, MD.

United statesTufiac haddadAntonio dassoroPractice innovationMayo clinic comprehensive cancer centerAntoniod assoroPuma biotechnologyAurka pathwayEndocrine resistant advanced breast cancerA phase 2 trial nct02860000Her2 negative metastatic breast cancer